Navigation Links
Emerging Agents from Theravance/Astellas, Johnson & Johnson/Basilea and Forest/Astrazeneca/Takeda Will Drive Modest Growth in the MRSA Drug Market Through 2018
Date:11/16/2009

WALTHAM, Mass., Nov. 16 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, over the next decade, modest growth in the methicillin-resistant Staphylococcus aureus (MRSA) drug market will be driven in part by the uptake of three emerging agents from Theravance/Astellas, Johnson & Johnson/Basilea and Forest/AstraZeneca/Takeda. The increasing prevalence of MRSA and the uptake of several premium-priced emerging therapies will drive the MRSA market to increase from $740 million in 2008 to more than $1 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The new Pharmacor report entitled Methicillin-Resistant Staphylococcus Aureus finds that Theravance/Astellas's telavancin, Johnson & Johnson/Basilea's ceftobiprole and Forest/AstraZeneca/Takeda's ceftaroline will capture more than one-third of the overall MRSA market in 2018. The two novel first-in-class anti-MRSA cephalosporins -- ceftobiprole and ceftaroline -- which are both expected to launch by 2011, will have a significant impact on the market by bringing cephalosporins to the forefront of the array of drug classes used to treat MRSA. Owing to their broad-spectrum and expanded activity against MRSA, ceftobiprole and ceftaroline are well-poised for use as first-line therapies for suspected MRSA infections in the hospital setting.

"Ceftobiprole and ceftaroline offer safe, effective, and convenient monotherapy options for simplified empiric treatment of MRSA infections in place of existing combination therapy," said Decision Resources Analyst Hemali Patel, Ph.D. "Although we anticipate robust competition between these two agents due to their similar profiles, we forecast that ceftobiprole and ceftaroline will each achieve significant commercial success and together will represent 20 percent of the overall MRSA market in 2018."

The report also finds that, in contrast to current therapies consisting largely of narrow-spectrum anti-MRSA agents, late-stage anti-MRSA emerging therapies are comprised of numerous broad-spectrum agents spanning several antibiotic drug classes. In addition, the pipeline for MRSA is also characterized by new therapies being developed in both intravenous and oral formulations (e.g., Trius Therapeutics' torezolid, Rib-X's delafloxacin, Paratek/Novartis's PTK-0796) which could address the growing need for oral MRSA therapies for both the hospital and community settings.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                  Decision Resources, Inc.
    Christopher Comfort                 Elizabeth Marshall
    781-296-2597                        781-296-2563
    ccomfort@dresources.com             emarshall@dresources.com

SOURCE Decision Resources


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Cantel Medical Corp. to Present at the Sidoti Emerging Growth Research Institutional Investor Forum
2. Xanodyne Raises $50 Million in Equity Financing to Support Emerging Product Portfolio
3. Cancer Drugs Emerging as Top Driver of Specialty Drug Spending
4. Frost & Sullivan Lauds Viatronix as European Medical Imaging Emerging Company of the Year
5. Patient-Targeted Messaging for Emerging Multiple Sclerosis Agents Needs to Highlight Efficacy and Preservation of Quality of Life
6. PAREXEL International to Present at William Blair Emerging Growth Stock Conference
7. Surveyed Neurologists Anticipate That Less Than 30 Percent of Their Use of Emerging Oral Agents in Multiple Sclerosis Will be in the First Line
8. Emerging Therapies Could Help Ease The Chronic Symptoms of Atopic Dermatitis For Adults and Children
9. Current and Emerging Drugs Continue to Struggle for Patient Share in the Treatment of Major Depressive Disorder
10. Malaria Vaccine Developer Sanaria Inc. Receives the Technology Council of Marylands Emerging Company of the Year Award
11. Revolution Health and EmergingMed Launch Cancer Clinical Trial Matching and Referral Service
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/15/2017)... 2017  Amy Baxter MD, chief executive officer and ... pain relief, was awarded a 2017 Top 40 Healthcare ... recognized at the MM&M Top 40 Healthcare Transformers dinner ... on May 10, 2017. The dinner followed a ... "beyond the pill."  "Innovation goes beyond invention," ...
(Date:5/10/2017)... , May 10, 2017 Global Health Intelligence ... Latin America , published its 2017 ranking of ... is based on extensive data analysis from GHI,s hospitals ... hospitals database for the region. The GHI database covers 86% ... offering more than 130 data points for each institution in ...
(Date:5/9/2017)... , May 9, 2017  Demonstrating its ... board of directors for the Pharmaceutical Research and ... for membership. Biopharmaceutical companies will now have to ... order to be eligible to join PhRMA. ... the board is sending a clear message that ...
Breaking Medicine Technology:
(Date:5/23/2017)... Beach, CA (PRWEB) , ... May 23, 2017 ... ... Certified Facial Plastic and Reconstructive Surgeon Dr. Kevin Sadati, is pleased to announce ... interested in building collagen and elastin in their face, neck, and body through ...
(Date:5/23/2017)... ... May 23, 2017 , ... MedTech ... in the modern ART laboratory, to provide hands-on training utilizing cutting-edge equipment at ... NextGen LifeLabs, a MedTech Group Purchasing vendor , will provide specialized equipment ...
(Date:5/23/2017)... ... May 23, 2017 , ... Orbita’s Nathan Treloar will discuss the role of ... Francisco. Titled Connected Health and IoT: Technology Innovators and Disruption , the workshop ... Associates, a market research and consulting firm specializing in emerging consumer technology products and ...
(Date:5/23/2017)... ... ... Therachat , a smart guided journaling tool for improving mental health, ... of anxiety in support of National Mental Health Awareness Month. , The nationwide survey ... general anxiety levels as well as identified the top triggers, impact to regular activities ...
(Date:5/22/2017)... ... 2017 , ... Patients who avoid necessary dental and endodontic treatments because of ... NY from Advanced Endodontics of Westchester. This highly-trained team of endodontists offer three different ... sedation methods may be recommended based on the severity of the anxiety experienced by ...
Breaking Medicine News(10 mins):